Although immune checkpoint inhibitors have revolutionized the treatment of patients with melanoma, identifying reliable biomarkers of response to this approach has proven to be exceedingly challenging, according to Douglas B. Johnson, MD, MSCI.
Archive | Health Professionals
Hunt for Reliable Biomarkers for Immunotherapy Continues in Melanoma
Posted in Melanoma News, Health Professionals, Of Interest
Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model
Since patients with stage I/IIA cutaneous melanoma (CM) are currently not eligible for adjuvant therapies despite relapse risk uncertainty, researchers examined the ability of a recently developed model that combines clinicopathologic and gene expression variables (CP-GEP) to identify patients with stage I/IIA melanoma who have a high risk for disease relapse.
Posted in Melanoma News, Health Professionals, Of Interest
Personalized Treatments, Overcoming Resistance Is Needed in Melanoma
With an estimated 5-year survival rate of 50% and an ongoing issue of resistance, Georgina Long, AO, BSc, PhD, MBBS, FRACPP, FAHMS, said that the next steps with immunotherapy in melanoma will focus on stratifying patients, personalizing therapy, and refining localized regimens.
Posted in Melanoma News, Health Professionals, Of Interest
Phase 2 Study Finds Nivolumab-Ipilimumab Combo Shows Activity in Metastatic Uveal Melanoma
A single-arm phase 2 study published in the Journal of Clinical Oncology found that the combination regimen of nivolumab (Opdivo) plus ipilimumab (Yervoy) demonstrates activity in metastatic uveal melanoma, with deep and sustained confirmed responses.
Posted in Melanoma News, Health Professionals, Clinical Trials
